New Insights and Potential Clinical Implications of the Odds Ratio Product (ORP)
October 24, 2023: Winnipeg, MB. Sleep has traditionally been analyzed in discrete stages assigned every 30 seconds based on visual feature detection. The Odds Ratio Product (ORP) measures wake/sleep state on a continuous scale leveraging the entirety of the electroencephalographic (EEG) signals. Simply put, ORP reflects the dynamic nature of sleep making it possible to distinguish different levels of sleep depth within the same conventional sleep stage, as well as it measures brief dynamic changes in sleep depth that cannot be obtained from the conventional staging approach.
The comprehensive analysis ORP provides is a major advance in our ability to better manage sleep disorders. Dr. Younes, inventor of the ORP methodology, in the recently published article “New Insights and Potential Clinical Implications of the Odds Ratio Product (ORP)” in Frontiers in Neurology, describes how ORP is measured, its validation and differences from delta power in the ability to measure sleep depth.
“ORP is novel as it directly translates EEG measurement of brain activity to a continuous metric of sleep depth, assessing spectral power in each frequency band relative to each other. This provides a comprehensive view of the EEG in a metric that easily transfers to clinical practice, improving the diagnosis and treatment of sleep disorders.” says Dr. Veronica Guadagni, Director, Sleep Science for Cerebra.
“Through the use of ORP we have identified different phenotypes among patients with sleep apnea (OSA), insomnia, and excessive sleep need (idiopathic hypersomnia). These different phenotypes may respond differently to the treatments currently offered for these disorders. Such differential responses to therapy now await confirmation through appropriate research projects, examples of which have been proposed/detailed in the Frontiers of Neurology article” says Dr. Magdy Younes, Distinguished Professor Emeritus, University of Manitoba and inventor of ORP.
Research continues to further the application of ORP into clinical practice. Cerebra is supporting this work by providing open access to ORP for sleep researchers with qualifying research proposals to advance the adoption of ORP into clinical practice. ORP is also available for clinical use in the Cerebra MY Sleep Scoring sleep diagnostic software. Any practitioner with unique or difficult patients that could benefit from a greater evaluation of sleep quality through the lens of ORP is encouraged to reach out to Cerebra.
The full paper is available for download below:
https://www.frontiersin.org/articles/10.3389/fneur.2023.1273623/full
Interested researchers and collaborators please contact directly:
Cerebra Sleep Science team at research@cerebrahealth.com
Interested clinicians please contact directly:
Cerebra Sales team at sales@cerebrahealth.com
##
About Cerebra
Cerebra is a Canadian technology company transforming the future of sleep diagnosis and therapy through its patented algorithm, Odds Ratio Product (ORP). ORP micro-analyses the Electroencephalogram (EEG) signal providing a continuous measure of sleep depth, moving beyond conventional scoring methods to dig deeper into brain activity. Cerebra unites innovators and researchers with the common goal and passion of putting “sleep” back into sleep medicine.